We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -106.00 | -0.87% | 12,050.00 | 12,036.00 | 12,038.00 | 12,178.00 | 12,010.00 | 12,092.00 | 1,635,146 | 16:35:23 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.34 | 186.61B |
From May 2019 to May 2024
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) reported results for the third quarter on Thursday. Here's what we looked at:
SALES: The British drug maker said sales in the quarter totaled $6.41 billion, ahead of analyst forecasts of $6.13 billion.
CORE EPS: Core earnings per share, a company metric looked at by analysts, was 99 cents, slightly exceeding market consensus expectations of 97 cents.
WHAT WE WATCHED:
TAGRISSO: Cancer drug Tagrisso confirmed its place as a key revenue driver for the company, accounting for 13% of its total sales. The drug generated $891 million in the quarter--which Shore Capital says is a 4% beat to analyst consensus expectations. The performance of the oncology portfolio overall was strong, with sales increasing by 48% at constant exchange rates.
CHINA: The FTSE 100-listed company's performance in China didn't seem to be losing steam despite earlier warnings by Chief Executive Pascal Soriot. Astra said that sales in the region increased by 40% excluding currency effects. Shore Capital said that it expects investors will react well to the drug maker's strength in emerging markets.
CASH FLOW: Earlier in the year, analysts had highlighted cash flow as one issue facing the company, particularly after a large deal to acquire part of the rights to the cancer asset DS-8201, but these seem to have abated. "Cash is the lifeblood of any company, so it is particularly encouraging to see such a strong performance here with the best part of a $1 billion inflow in the period after capital expenditure," says AJ Bell.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
October 24, 2019 08:54 ET (12:54 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
